New Enterprise Associates 14, L.p. - Net Worth and Insider Trading

New Enterprise Associates 14, L.p. Net Worth

The estimated net worth of New Enterprise Associates 14, L.p. is at least $262 Million dollars as of 2024-04-29. New Enterprise Associates 14, L.p. is the 10% Owner of Adaptimmune Therapeutics PLC and owns about 82,978,668 shares of Adaptimmune Therapeutics PLC (ADAP) stock worth over $89 Million. New Enterprise Associates 14, L.p. is the 10% Owner of Oyster Point Pharma Inc and owns about 5,925,287 shares of Oyster Point Pharma Inc (OYST) stock worth over $66 Million. New Enterprise Associates 14, L.p. is also the 10% Owner of Casper Sleep Inc and owns about 6,222,412 shares of Casper Sleep Inc (CSPR) stock worth over $42 Million. Besides these, New Enterprise Associates 14, L.p. also holds Mersana Therapeutics Inc (MRSN) , Imara Inc (IMRA) , Champions Oncology Inc (CSBR) , Surface Oncology Inc (SURF) , Galera Therapeutics Inc (GRTX) , TRACON Pharmaceuticals Inc (TCON) , Appian Corp (APPN) . Details can be seen in New Enterprise Associates 14, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that New Enterprise Associates 14, L.p. has not made any transactions after 2022-04-06 and currently still holds the listed stock(s).

Transaction Summary of New Enterprise Associates 14, L.p.

To

New Enterprise Associates 14, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, New Enterprise Associates 14, L.p. owns 18 companies in total, including Mersana Therapeutics Inc (MRSN) , Surface Oncology Inc (SURF) , and Imara Inc (IMRA) among others .

Click here to see the complete history of New Enterprise Associates 14, L.p.’s form 4 insider trades.

Insider Ownership Summary of New Enterprise Associates 14, L.p.

Ticker Comapny Transaction Date Type of Owner
MRSN Mersana Therapeutics Inc 2019-08-28 10 percent owner
SURF Surface Oncology Inc 2020-05-20 10 percent owner
IMRA Imara Inc 2022-04-06 10 percent owner
CSBR Champions Oncology Inc 2020-03-06 10 percent owner
CSPR Casper Sleep Inc 2020-02-10 10 percent owner
GRTX Galera Therapeutics Inc 2019-11-12 10 percent owner
OYST Oyster Point Pharma Inc 2019-11-04 10 percent owner
ADAP Adaptimmune Therapeutics PLC 2018-09-07 10 percent owner
MULE MuleSoft Inc 2018-05-01 10 percent owner
TCON TRACON Pharmaceuticals Inc 2018-03-27 10 percent owner
APPN Appian Corp 2017-11-27 10 percent owner
SYBX Synlogic Inc 2015-09-30 10 percent owner
SBBP Strongbridge Biopharma PLC 2018-01-01 10 percent owner
ILIU Interleukin Genetics Inc 2016-07-29 10 percent owner
AVTX Avalo Therapeutics Inc 2015-10-14 10 percent owner
LOXO Loxo Oncology Inc 2014-07-31 10 percent owner
ZFOX ZeroFox Holdings Inc 2022-08-03 10 percent owner
ELVN Enliven Therapeutics Inc 2020-03-11 10 percent owner

New Enterprise Associates 14, L.p. Latest Holdings Summary

New Enterprise Associates 14, L.p. currently owns a total of 10 stocks. Among these stocks, New Enterprise Associates 14, L.p. owns 82,978,668 shares of Adaptimmune Therapeutics PLC (ADAP) as of September 7, 2018, with a value of $89 Million and a weighting of 34.08%. New Enterprise Associates 14, L.p. owns 5,925,287 shares of Oyster Point Pharma Inc (OYST) as of November 4, 2019, with a value of $66 Million and a weighting of 25.28%. New Enterprise Associates 14, L.p. also owns 6,222,412 shares of Casper Sleep Inc (CSPR) as of February 10, 2020, with a value of $42 Million and a weighting of 16.12%. The other 7 stocks Mersana Therapeutics Inc (MRSN) , Imara Inc (IMRA) , Champions Oncology Inc (CSBR) , Surface Oncology Inc (SURF) , Galera Therapeutics Inc (GRTX) , TRACON Pharmaceuticals Inc (TCON) , Appian Corp (APPN) have a combined weighting of 24.53% among all his current holdings.

Latest Holdings of New Enterprise Associates 14, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ADAP Adaptimmune Therapeutics PLC 2018-09-07 82,978,668 1.08 89,202,068
OYST Oyster Point Pharma Inc 2019-11-04 5,925,287 11.17 66,185,456
CSPR Casper Sleep Inc 2020-02-10 6,222,412 6.78 42,187,953
MRSN Mersana Therapeutics Inc 2019-08-28 11,959,520 2.94 35,160,989
IMRA Imara Inc 2022-04-06 2,611,050 6.32 16,501,836
CSBR Champions Oncology Inc 2020-03-06 1,713,720 5.02 8,602,874
SURF Surface Oncology Inc 2020-05-20 2,892,877 1.07 3,095,378
GRTX Galera Therapeutics Inc 2019-11-12 4,358,047 0.19 811,033
TCON TRACON Pharmaceuticals Inc 2018-03-27 17,330 1.81 31,367
APPN Appian Corp 2017-11-27 0 37.56 0

Holding Weightings of New Enterprise Associates 14, L.p.


New Enterprise Associates 14, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, New Enterprise Associates 14, L.p. has made a total of 0 transactions in Adaptimmune Therapeutics PLC (ADAP) over the past 5 years. The most-recent trade in Adaptimmune Therapeutics PLC is the acquisition of 3,000,000 shares on September 7, 2018, which cost New Enterprise Associates 14, L.p. around $5 Million.

According to the SEC Form 4 filings, New Enterprise Associates 14, L.p. has made a total of 1 transactions in Oyster Point Pharma Inc (OYST) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Oyster Point Pharma Inc is the acquisition of 935,000 shares on November 4, 2019, which cost New Enterprise Associates 14, L.p. around $15 Million.

According to the SEC Form 4 filings, New Enterprise Associates 14, L.p. has made a total of 1 transactions in Casper Sleep Inc (CSPR) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Casper Sleep Inc is the acquisition of 1,250,000 shares on February 10, 2020, which cost New Enterprise Associates 14, L.p. around $15 Million.

More details on New Enterprise Associates 14, L.p.'s insider transactions can be found in the Insider Trading History of New Enterprise Associates 14, L.p. table.

Insider Trading History of New Enterprise Associates 14, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

New Enterprise Associates 14, L.p. Trading Performance

GuruFocus tracks the stock performance after each of New Enterprise Associates 14, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by New Enterprise Associates 14, L.p. is 16.2%. GuruFocus also compares New Enterprise Associates 14, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by New Enterprise Associates 14, L.p. within 3 months outperforms 7 times out of 13 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how New Enterprise Associates 14, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of New Enterprise Associates 14, L.p.

Average Return

-11.31%

Average return per transaction

Outperforming Transactions

31%

4 out of 13 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 3.37 16.2 1.57 -11.31 -31.85 -21.72
Relative Return to S&P 500(%) 1.31 11.4 -5.88 -26.4 -42.9 -33.81

New Enterprise Associates 14, L.p. Ownership Network

Ownership Network List of New Enterprise Associates 14, L.p.

No Data

Ownership Network Relation of New Enterprise Associates 14, L.p.


New Enterprise Associates 14, L.p. Owned Company Details

What does Mersana Therapeutics Inc do?

Who are the key executives at Mersana Therapeutics Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Mersana Therapeutics Inc. Other key executives at Mersana Therapeutics Inc include director & President and CEO Anna Protopapas , SVP & Chief Development Officer Mohan Bala , and Chief Manufacturing Officer Tushar Misra .

Mersana Therapeutics Inc (MRSN) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in Mersana Therapeutics Inc (MRSN). Other recent insider transactions involving Mersana Therapeutics Inc (MRSN) include a net sale of 9,107 shares made by Alejandra Carvajal , a net sale of 5,723 shares made by Tushar Misra , and a net sale of 46,745 shares made by Anna Protopapas .

In summary, during the past 3 months, insiders sold 0 shares of Mersana Therapeutics Inc (MRSN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 114,354 shares of Mersana Therapeutics Inc (MRSN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 114,354 shares.

Mersana Therapeutics Inc (MRSN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Mersana Therapeutics Inc Insider Transactions

No Available Data

New Enterprise Associates 14, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for New Enterprise Associates 14, L.p.. You might contact New Enterprise Associates 14, L.p. via mailing address: 1954 Greenspring Drive, Suite 600, Timonium Md 21093.

Discussions on New Enterprise Associates 14, L.p.

No discussions yet.